Panthera CryoSolutions Inc.

PanTHERA CryoSolutions is a Canadian biotechnology company developing ice recrystallization inhibitor (IRI) technology to improve the preservation of frozen cells. Its products are designed to reduce damage during cryopreservation, limit the effects of conventional cryoprotective agents such as DMSO, glycerol, and HES, and protect samples from temperature fluctuations during storage and shipping. By supporting better post-thaw cell recovery, viability, and functionality, the technology aims to help researchers and organizations preserve higher-quality cellular materials.

PanTHERA’s IRIs can be added to existing cryopreservation solutions and may enable the use of lower amounts of conventional cryoprotectants. In some applications, they also allow samples to be stored at higher sub-zero temperatures, potentially reducing reliance on costly liquid nitrogen systems and specialized shipping containers. The company’s platform is intended for a broad range of uses, including research and development, cell and gene therapies, organ, tissue, and blood banking, biomanufacturing, assisted reproductive technologies, and animal and aquaculture breeding and preservation. PanTHERA also shares science, product, and industry information through its publications, news, events, and blog.